yingweiwo

STAT

STAT

The cytoplasmic protein family STAT controls a variety of cellular processes, including cell growth, survival, and differentiation. The Janus kinase family of transcription factors is activated, and dysregulation of this pathway, which promotes angiogenesis, tumor survival, and immunosuppression, is frequently seen in primary tumors. Gene knockout studies have shown that STAT proteins are important for immune system development and operation, immune tolerance maintenance, and tumor surveillance.

STAT related products

Structure Cat No. Product Name CAS No. Product Description
(E/Z)-OSM-SMI-10B V87055 (E/Z)-OSM-SMI-10B 2502294-55-3 (E/Z)-OSM-SMI-10B is a derivative of OSM-SMI-10.
(R,R)-VVD-118313 V51515 (R,R)-VVD-118313 2875046-31-2 (R,R)-VVD-118313 is the seven bodies of VVD-118313.
(trans)-STAT6 modulator-5 V117718 (trans)-STAT6 modulator-5 (trans)-STAT6 regulator-5 (compound 95) is a STAT6 protein regulator that inhibits the STAT6 signaling pathway.
(trans)-STAT6-IN-13 V122282 (trans)-STAT6-IN-13 (trans)-STAT6-IN-13 is a STAT6 inhibitor with an IC50 value ≤300 nM.
15(R)-Lipoxin A4 V102604 15(R)-Lipoxin A4 171030-11-8 15(R)-Lipoxin A4 (15-epi-LXA4) is a STAT-6 activator and lipid-derived lipoxin-type resolution mediator (SPM) that promotes the resolution of inflammation and regulates immune cell function.
2-Chloro-5-(trifluoromethyl)pyrimidine V124569 2-Chloro-5-(trifluoromethyl)pyrimidine 69034-12-4 2-Chloro-5-(trifluoromethyl)pyrimidine is a chemical intermediate.
5-FAM-GpYLPQTV-NH2 V85008 5-FAM-GpYLPQTV-NH2 769166-98-5
5-FAM-GpYLPQTV-NH2 TFA V87041 5-FAM-GpYLPQTV-NH2 TFA 5-FAM-GpYLPQTV-NH2 (TFA) is a fluorescently labeled peptide with STAT3 inhibitory activity.
Ac-GpYLPQTV-NH2 V85002 Ac-GpYLPQTV-NH2 1349616-70-1
Ac-GpYLPQTV-NH2 acetate V106122 Ac-GpYLPQTV-NH2 acetate Ac-GpYLPQTV-NH2 acetate is a STAT3 inhibitor with IC50 of 0.33 μM.
AKR1B1/STAT3/SLC7A11-regulator-1 V128440 AKR1B1/STAT3/SLC7A11-regulator-1 2632263-80-8 AKR1B1/STAT3/SLC7A11-regulator-1 is an AKR1B1/STAT3/SLC7A11 regulator that reverses doxorubicin resistance in MCF-7/ADR cells by enhancing ferroptosis activity.
Anti-inflammatory agent 92 V101159 Anti-inflammatory agent 92 1609387-77-0 Anti-inflammatory agent 92 (compound LD4) is a porphyrin derivative.
Anticancer agent 259 V104473 Anticancer agent 259 Anticancer agent 259 (compound 3g) is a telmisartan-based cell death regulator that interferes with the STAT5 signaling pathway and enhances the sensitivity of resistant cells to imatinib, with a SC50 of 1.5 μM.
Antitumor agent-195 V129179 Antitumor agent-195 Antitumor agent-195 is a dual-target drug targeting STAT3 and NQO1.
AX-202 V129696 AX-202 AX-202 is a humanized IgG4 monoclonal antibody that targets S100A4.
Betavulgarin V130089 Betavulgarin 51068-94-1 Betavulgarin is an anticancer agent.
BML-260 V87064 BML-260 101439-76-3 BML-260 is a potent dual-specific phosphatase inhibitor of JSP-1 and DUSP22.
C188-9 V3113 C188-9 432001-19-9 C188-9 is a novel, potent and orally bioavailable STAT3 inhibitorthat binds to STAT3 with high affinity (KD=4.7±0.4 nM).
Cappariloside A V131012 Cappariloside A 229483-41-4 Cappariloside A is a larvicidal agent that has larvicidal activity against Aedes aegypti mosquito larvae and reduces the activity of glutathione S-transferase in larvae.
CDK8/19-IN-2 V87057 CDK8/19-IN-2 3024381-54-9 CDK8/19-IN-2 (compound 12) is an orally available inhibitor of cell cycle-dependent kinase 8/19 (CDK8 and CDK19) with IC50 values of 2.08 and 2.49 nM, respectively.
Contact Us